Healthcare Biz Wrap: BioTime Bids For Geron Assets, Lilly Gets Positive Opinion
The board of directors of Geron Corporation (NASDAQ:GERN) confirms that it received a letter from BioTime (AMEX:BTX), offering to purchase its stem cell assets, and saying that it will review and act in a manner that it believes will be in the best interests of the former’s stockholders. The board says that it has been considering several alternatives since the firm discontinued both its stem cell research and development programs.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
Insurers seem to be taking a cautious outlook on Questcor Pharmaceuticals’ (NASDAQ:QCOR) Acthar, says a Citron Research report, which now claims that Humana (NYSE:HUM) has released a new Commercial Preauthorization document that contains a new, specifically asterisked preauthorization for reimbursement for Acthar, which it says is part of a pattern of insurers taking a more restrictive stance on authorization policy linked to the drug’s reimbursement.
Eli Lilly and Company (NYSE:LLY) has received a positive opinion from the Committee for Medicinal Products for Human Use in Europe, which recommends approval of Amyvid, that is a solution for injection as a diagnostic radiopharmaceutical in the brains of adult patients being studied for Alzheimer’s Disease and other causes of cognitive impairment.
Don’t Miss: Pfizer Sheds Some Good-Bye Tears Over This.